Neutral
●
PRNewsWire
●
6 months ago
NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D.